Ruben Mesa, MD
Advertisement
Articles by Ruben Mesa, MD
Advertisement
Latest Updated Articles
Making a Differential Diagnosis of MyelofibrosisPublished: May 12th 2022 | Updated:
Factors in Selecting Therapy for MyelofibrosisPublished: May 26th 2022 | Updated:
Overview on Essential Thrombocythemia and Polycythemia Vera ManagementPublished: December 22nd 2022 | Updated:
- Use of Ruxolitinib in Myelofibrosis
Published: June 2nd 2022 | Updated:
Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in MyelofibrosisPublished: October 16th 2020 | Updated:
- Clinical Pearls for the Management of Myelofibrosis
Published: June 23rd 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5